Quarterly Activities/Appendix 4C Cash Flow Report
| Stock | Clarity Pharmaceuticals Ltd (CU6.ASX) |
|---|---|
| Release Time | 31 Jan 2025, 11:57 a.m. |
| Price Sensitive | Yes |
Clarity Pharmaceuticals Reports Quarterly Activities and Cash Flow
- Strong cash position of $122 million to fund operations through mid-2026
- Positive results from SECuRE trial of 67Cu-SAR-bisPSMA, including complete response in a patient
- Received Fast Track Designation from FDA for 64Cu-SAR-bisPSMA in prostate cancer patients with biochemical recurrence
- Progressing AMPLIFY and CLARIFY pivotal trials for 64Cu-SAR-bisPSMA diagnostic
Clarity Pharmaceuticals reported a strong cash position of $122 million, which is expected to fund operations through mid-2026. The company made significant progress in its clinical programs, including positive results from the SECuRE trial of 67Cu-SAR-bisPSMA, where a patient achieved a complete response. Clarity also received Fast Track Designation from the FDA for 64Cu-SAR-bisPSMA in prostate cancer patients with biochemical recurrence, enabling accelerated development. The company is progressing its pivotal trials, AMPLIFY and CLARIFY, for 64Cu-SAR-bisPSMA diagnostic. Clarity expanded its pipeline with a novel Fibroblast Activation Protein (FAP)-targeted radiopharmaceutical called SAR-bisFAP, which is a promising pan-cancer product for diagnosis and treatment. The company also strengthened its supply and manufacturing capabilities through agreements with Nucleus RadioPharma and SpectronRx. Clarity's clinical data continues to be recognized at leading conferences, further validating the potential of its products. The company's inclusion in the ASX200 index is a significant milestone, reflecting the growth and success of the Australian biotech company.
Clarity's cash position of $122 million, including $11 million in R&D tax incentive receivable, is expected to provide runway through mid-2026, supporting the continued advancement of its diagnostic and therapeutic pipeline.
Clarity remains well-funded and is leveraging the momentum of its impressive clinical data, strong science, and the growing radiopharmaceutical sector to advance its differentiated platform of diagnostic and therapeutic assets with the goal of improving outcomes for cancer patients globally.